Medical Research

Community information
The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
  • Health plans push for their members to visit their primary care provider for a checkup. It improves health outcomes and reduces the medical spend from costs related to illness and disease. Like their members, health plans also need checkups that will identify the challenges to which they are increasingly exposed, such as issues around information security, revenue maximization, and staffing needs. In this webinar, we will discuss how to specifically deal with key issues related to each of these areas.
  • Key topics:
    *Emerging markets context
    *EU5 vs. Emerging Markets comparison – similarities and differences
    *Rep-reach: How different coverage influences digital preferences
    *Understanding the digital gap
  • Semiconductor nanostructures possess a number of applications in solar energy conversion. This includes using colloidal quantum dots in solar cells and, more recently, using analogous nanostructures such as nanowires (NWs) and nanosheets (NSs) in photocatalytic applications. In this presentation, we describe recent work to understand the photocatalytic response of solution-synthesized CdSe NWs and CdS NSs within the context of hydrogen generation. Various CdSe NW- and CdS NS-based systems such as core/shell structures and hybrid metal nanoparticle/semiconductor hybrid systems have been studied. In all cases, femtosecond transient differential absorption spectroscopy has been used to reveal relevant carrier relaxation processes in these materials as well as the flow of charges across the different heterointerfaces that are present. By correlating these transient absorption kinetics to results from accompanying hydrogen generation quantum yield measurements, we have, in turn, rationalized the response of these materials, clarifying the role that different heterojunctions play in establishing both charge separation and hydrogen generation efficiencies.
  • Highlighting the success of Arkansas' quality rewards-based payment reform initiative: costs savings and quality care improvement.
  • This webinar will focus on operations and maintenance of the StatSpin Express 3 centrifuge. By performing simple inspections, routine maintenance and operating the centrifuges as described in this webinar, you can maximize your StatSpin Express 3 uptime and sustain your productivity.
  • Patient Engagement is every Provider’s new “highest priority,” but to date, much of the focus has been on driving patients to portals as a means to engage. Innovative providers are moving the focus to other arenas including social channels in order to engage people where they are spending their time.

    Join this webinar, where Janice Jacobs and Stephanie Bartels, will discuss the key components of a successful comprehensive patient engagement program that includes social strategies. Learn about a host of Patient Engagement solutions and a focused discussion around how to get started in social media, how to use social media to increase patient satisfaction and acquisition, and potentially even affect clinical outcomes. Janice and Stephanie will also discuss how to interact, educate and lead the healthcare conversation on social media, social media listening and reputation management and challenges and opportunities with social engagement for providers.
  • Healthcare is in the midst of a data-driven revolution. Successful healthcare organizations will be those that can use analytics effectively to guide care decisions, create effective population health strategies and use resources efficiently. Join Dr. Thomas Hill and healthcare thought leaders for this interactive panel discussion at 1:30 pm on October 20th, Executive Summit, Dell World 2015 in Austin, Texas. In this session, you will hear practical tips for how healthcare organizations can successfully embrace modern data-driven technologies and deliver better healthcare outcomes and financial performance.
  • Harvard Pilgrim Health Care was ranked the number one health plan in America for 10 years. Technology is extremely important at Harvard Pilgrim. The worst case scenario would be for one of their members to end up in the emergency room and be denied coverage. So they need to make sure they get things right and that they are timely about it.

    Hear how Harvard Pilgrim Health Care worked with Dell to come up and IT strategy to replace their claims adjudication engine as well as a number of systems that surround it.
  • Achieving your ADME/Tox testing goals requires experience, quality data, and proper alignment with regulatory guidance. Failure to meet these important requirements can put your drug discovery and pre-clinical goals at risk.
    This presentation will provide an informative overview of how you can advance and reach your pre-clinical drug discovery goals. It will discuss the importance of core contract research capabilities, including enzyme induction, enzyme inhibition, and transporter interaction. In addition, we will review new capabilities and opportunities including CYP induction and SLC transporter assay services – all designed to align with regulatory agency guidance documents.

    Speaker Bio:
    David Stresser is the Program Manager of Corning® Gentest℠ Contract Research Services at Corning Life Sciences since 2001, having held prior positions of Product Manager and Study Director since joining Corning in 1998. Prior to this, he was a post-doctoral associate in the laboratory of David Kupfer at the University of Massachusetts Medical School in Worcester, Massachusetts. He did his graduate work in the laboratory of David E. Williams at Oregon State University in Corvallis, Oregon receiving a Ph.D. in toxicology in 1994. Dr. Stresser has authored or co-authored 40 articles or book chapters in the field of drug metabolism and has been an invited speaker at various national and international meetings, pharmaceutical companies, and universities.
  • Presentation 1: Jason Causon, Senior Applications Specialist, Sciex

    Development of bioanalytical LC-MS methods for the detection of therapeutic peptides and the proteolytic fragments of larger proteins and antibodies is growing along with the increasing number of peptide and protein drugs entering clinical research and development. Development of these methods present challenges that are different to small molecule method development because of the multiple charge states possible for a given peptide, the abundance of product ion possibilities and the large number of proteolytic fragments possible from a protein digest. In addition to optimizing for sensitivity, on-column HPLC method development is time consuming for the same reasons. In this webinar we present an automated tuning and optimization workflow with on-column validation using DiscoveryQuantTM 3.0 software with the new ChromaTune feature to overcome some of these challenges and make the optimization of peptide MRM methods easier and less time consuming.

    Presentation 2: Remco van Soest, Product Manager, Sciex

    Electrospray Ionization efficiency increases at lower flow rates. In this Webinar we will discuss how microLC can help you improve sensitivity in sample limited applications in bio-analysis by LC-MS. In order to analyse the same volume of sample as is typically injected in a conventional LC-MS system, up to 50 µL, we have developed a microLC system that allows for fast on-line pre-concentration on a short trap column. Because of the higher flow rates that can be used for loading the sample on the trap-column, sample throughput is not affected by using microLC flow rates for the LC-MS analysis.
  • Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market: it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

    Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the worlds aging populations. In contrast, stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.

    Join us as we discuss these and other key topics.
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Computer Aided Synthetic Design: How ARChem Can Improve Your Efficiency and Creativity

    Are you looking for a better way to synthesize a target molecule?

    Have you hit a roadblock in the lab or need an extra burst of creative thinking?

    Join Orr Ravitz at 10:00 AM (EDT) on July 16th for an overview of the future of synthetic design and the software that can help improve your efficiency and creativity in the lab with ARChem.

    He will discuss how medicinal chemists, process chemists and material scientists use ARChem as an idea generator – a tool for route scouting, for brain storming sessions, for the daily synthesis planning and potentially provide an alternative that gets you to curated experimental pathways faster than exploring the literature.

    This webinar will cover:

    ◦The technology behind ARChem and real life case studies
    ◦How ARChem can improve your productivity and creativity in the lab
    ◦Future developments of our synthetic design software
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • How to Prepare and What to Ask of Your Suppliers:

    In an effort to thwart fraudulent medical manufacturing practices, the European Commission published a Commission Recommendation (2013/473/EU) focusing on the assessment and auditing practices of notified bodies in the field of medical devices.
    A particular emphasis in this Recommendation has been placed on unannounced audits. Unannounced audits are additional assessments by notified bodies of manufacturers and/or their critical material suppliers. Auditors commissioned by the notified body will be able to arrive on site without giving the manufacturer prior notice and proceed with inspection. Over 5,000 unannounced audits are expected this year alone and come in addition to the initial surveillance or renewal audits of a three-year certification cycle.

    Now is the time to make sure you and your supplier’s quality and supply chain management systems are in place and you have full transparency. Join us for this informational webinar discussing this trending regulatory standard and learn about what you and your suppliers should be doing to proactively prepare.
  • Though single-use technology and the general use of disposables are widely accepted and applied both in process development, pilot plant and selected production processes, they are not in general a reasonable choice at any scale or application. Notably process chromatography is considered a critical unit operation regarding feasibility to single-use application with the chromatographic matrix assumed to be the typical cost driver. But is this really true? The answer to this quite ambivalent: it depends! Numerous young and innovative companies have developed new and/or alternative products which can help to significantly reduce the costs of goods, thus providing an interesting basis for single-use applications. After all, taking into account reasonable scales and suitable manufacturing targets, the doors have been opened widely due to the supply of appropriate low-cost matrices and feasible hardware.
  • Life sciences companies need to make better use of the insights that real world data (RWD) can provide in order to improve market access, sales and market growth strategies – and ultimately to improve the applicability of new and existing therapeutics for patients. Insights come not just from the multiple sources of RWD available, but from advanced analytics that highlight the effectiveness of a treatment by geographic area, and link healthcare providers, institutions and patients to relevant and meaningful outcomes.

    This one-hour event will take a hands-on approach – detailing how insights derived from RWD (and collaboratively with other sources) are enabling all elements of the life science industry to do things better.

    Insights experts Robin Munro and Christian Marcazzo will deliver case studies on how RWD can help life science companies in:

    Sales and Marketing – incorporate RWD and evidence into segmentation, targeting, and engagement of physicians and institutions
    Commercial Effectiveness – measure commercial campaigns, and demonstrate the impact to the healthcare system
    Medical Affairs – find and engage medical education prospects and target appropriate healthcare authorities, healthcare professionals and payers, to improve quality of care and outcomes
    Public Affairs and Market Access – develop qualitative and quantitative insights to design education, advocacy and access-related campaigns within the healthcare ecosystem

    The event will also give an exclusive look at what can be achieved from combining data sources – using Diabetes in England as a case study, Zephyr has implemented novel methods to demonstrate an evidence-based approach to improving information sharing within sales teams and to engaging accounts and payers. We explore how patient outcomes from RWD can add value to commercial strategy.
  • Join this webinar to hear case studies and key success factors in using real world data and market insights for more targeted, successful brand launches.

    Our industry is on the precipice of moving from the pharmaceutical age to the data age in healthcare. Working with Zephyr Health, this webinar will discuss concepts such as data maturity, achieving decision excellence and ultimately why those companies which embrace the untapped opportunities available now will rapidly develop competitive advantage.

    Zephyr Health experts Sven Junkergärd and Christian Marcazzo join pharmaphorum’s Paul Tunnah to discuss how and why brand launches can be accelerated through intelligent and innovative use of data, and drawing from their extensive experience, show what you can do to implement these learnings.
  • Wébinaire présenté par Sigma Aldrich:
    Audits Inopinés: Etes vous prêts?
    - Comment les préparer avec vos fournisseurs
    - Les connaissez vous vraiment
    - Savez vous comment ils se préparent
    - Etes vous prêts
    Afin de prévenir de possibles pratiques frauduleuses dans la fabrication de dispositifs médicaux, la Commission Européenne a publié la Recommandation 2013/473 / EU sur les audits et évaluations réalisés par les organismes notifiés, dans le cadre de la mise en oeuvre des Mesures d'action immédiate post- PIP.
    Un des changement important introduit par cette recommandation concerne les audits inopinés des sous-traitants déterminants et fournisseurs essentiels de matières premières. Les auditeurs des organismes notifiés peuvent auditer leur site de fabrication au même titre que le fabricant du dispositif médical.
    Le chiffre de 5000 audits inopinés est avancé par les organismes notifiés pour cette année, en plus des audits de surveillance et de certification classiques. Ils sont en premier lieu prévus sur les sites des fabricants de dispositifs médicaux, et peuvent désormais être étendus aux sous-traitants et fournisseurs.
    C'est le moment d'évaluer le système qualité et la chaine d'approvisionnement des fournisseurs de vos matières premières critiques. Nous vous invitons à vous joindre à notre wébinaire "Audits Inopinés: Etes vous prêts?" dans lequel nous parlerons des implications de cette Recommandation sur les relations avec les fournisseurs et comment s'y préparer:
    Les sujets abordés:
    - qu'est ce qu'un audit inopinés et quel est son périmètre d'évaluation
    - que recherchent les organismes notifiés pendant un audit inopiné
    - quelle est la définition d'un fournisseur essentiel
    - les questions à poser aux fournisseurs de matières premières critiques pour se préparer
  • The latest technology solving problems in your laboratory.
    Automatically. The webinar will cover:
    - Introduction to Automated Intelligent Morphology
    - Performance of the DxH AIM technology in real-life examples
    - Case studies showing AIM at work
  • Webinar presentado por Sigma-Aldrich:
    Las auditorías sin previo aviso: ¿Está usted listo?
    Cómo prepararse y Qué preguntar a sus proveedores
    ¿Las conoce?.
    ¿Sabe cómo las realizan?.
    ¿Está usted preparado?
    En un esfuerzo por impedir las prácticas fraudulentas en la fabricación de dispositivos médicos, la Comisión Europea publicó la recomendación (2013/473 / UE) centrándose en las prácticas de evaluación y auditoría de los organismos notificadores en el campo de los dispositivos médicos.
    Hay una especial atención y preocupación por las auditorías sin previo aviso. Éstas, que no son anunciadas, son evaluaciones adicionales de los organismos competentes a los fabricantes y/o proveedores de las materias críticas. Los auditores encargados por el organismo notificador podrán auditar sin previo aviso sus instalaciones o fábricas y proceder a su inspección. Más de 5.000 auditorías sin previo aviso se esperan para este año y se suman a las auditorías de vigilancia y de renovación de ciclos de certificación por tres años.
    Es el momento para asegurarse que los sistemas de gestión de la calidad y la cadena de suministro de su proveedor están correctamente y tienen una total transparencia. Únase a nosotros a este seminario informativo y así poder debatir esta nueva tendencia de regulaciones y aprender sobre lo que usted y sus proveedores deben hacer para prepararse de forma proactiva.
    ¿Qué conocerá?:
    - La auditoria sin previo aviso y el alcance de su valoración.
    - Quienes son los organismos notificadores y lo que van a pedir en una auditoria sin previo aviso.
    - Qué o quién es para la Comisión Europea un proveedor crítico.
    - Las preguntas que usted debería hacer a sus proveedores de materias primas sobre sus sistemas de gestión, cadena de suministro y calidad.
  • Standardizing feeding protocols in the Neonatal Intensive Care Unit for very low birth-weight infants
  • Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market; it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

    Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the world’s aging populations. In contrast, the stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late-stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out, as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.
  • What you will learn about the AU5800 chemistry analyzer:
    - Typical performance observed.
    - Impact on the laboratory's turnaround time targets.
    - Operator feedback on instrument features.
    - Instrument uptime metrics.
  • Vitamin D has traditionally been closely linked to bone health. It prevents rickets in children, as well as lowers the risk of fracture and osteoporosis in adults and the elderly. The links between vitamin D and bone health will be highlighted as part of the upcoming World Osteoporosis Day on 20th October 2015.

    Articles discussing the diverse positive effects of vitamin D have recently been hitting the headlines, with 3,500 studies published every year and ongoing research into its emerging health benefits. Despite this, 88% of the global population have low vitamin D intake due to poor nutrition and sun exposure. There is still a lack of knowledge among consumers about the long-term effects of vitamin D deficiency.

    Join our webinar on vitamin D and its health benefits, which will be presented by the acclaimed scientist in biochemistry and molecular biology, Dr. Bruce Ames. He will be accompanied by DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly. They will present the latest findings on vitamin D and the emerging benefits across different life stages and conditions. Dr. Ames will also discuss his groundbreaking triage theory, which demonstrates that when micronutrients are scarce, the body uses them to compensate the episodic shortages at the expense of long-term survival, which leads to potential DNA damage and negative effects on human health.
  • Recordkeeping for purposes of regulatory compliance in the modern radiation oncology environment is largely a paper driven process. Many software and hardware solutions are available from vendors to solve individual issues relating to the collection and processing of QA data, but few, if any, can collect, process and present the results of this data in a cohesive way.

    This presentation will show how electronic recordkeeping is readily and routinely used in the setting of Radiology and Nuclear Medicine Service lines, but strangely absent in the Oncology service line. We will attempt to cover current offerings from oncology software vendors that aim to reduce the amount of paperwork and streamline the acquisition and processing of quality assurance data. In addition, we will provide an overview of the solution we are in the process of implementing at our facility.

    Goals and Objectives
    At the conclusion of the program, participants will be able to:

    -Identify the use of electronic recordkeeping in other areas of the hospital setting where radiation and radioactive materials are being utilized.

    - Assess the need for some form of comprehensive recordkeeping in Radiation Oncology.

    - Assess currently available offerings from vendors.

    - Discuss what our facility is implementing to fill this need

    Target Audience
    Medical Physicists, Oncology IT professionals, Oncology Administrators

    CEUs
    Pending approval for ASRT, MDCB & MPCEC for 1 credit
  • Vitamin D has traditionally been closely linked to bone health. It prevents rickets in children, as well as lowers the risk of fracture and osteoporosis in adults and the elderly. The links between vitamin D and bone health will be highlighted as part of the upcoming World Osteoporosis Day on 20th October 2015.

    Articles discussing the diverse positive effects of vitamin D have recently been hitting the headlines, with 3,500 studies published every year and ongoing research into its emerging health benefits. Despite this, 88% of the global population have low vitamin D intake due to poor nutrition and sun exposure. There is still a lack of knowledge among consumers about the long-term effects of vitamin D deficiency.

    Join our webinar on vitamin D and its health benefits, which will be presented by the acclaimed scientist in biochemistry and molecular biology, Dr. Bruce Ames. He will be accompanied by DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly. They will present the latest findings on vitamin D and the emerging benefits across different life stages and conditions. Dr. Ames will also discuss his groundbreaking triage theory, which demonstrates that when micronutrients are scarce, the body uses them to compensate the episodic shortages at the expense of long-term survival, which leads to potential DNA damage and negative effects on human health.
  • Lung cancer is the number one cancer globally and the leading cause of cancer related deaths. Join Peter Bela Illei, M.D., Assistant Professor of Pathology and Oncology, Johns Hopkins Medicine on September 23 at 9 AM MST, he will address the key challenges and considerations for effectively managing lung cancer testing now and in the future.
  • Business requirements and technology trends are constantly on a change. Organizations are looking for partners who can provide solutions that are scalable and built on extensible architectures to support global needs with faster time-to-market and lower costs. Dell Application Development Maintenance and Support (ADMS) services cut across industries and verticals with expertise and capability in a host of technology platforms Microsoft, Java, Open source, Mainframe and other legacy platforms. We have partnered with niche players as well as leading vendors like Oracle, IBM and SAP in their database and platform solutions.

    Attend this webinar to learn how Dell Application Development and Maintenance services can help build a scalable and growth-focussed enterprise.
  • The webinar will review the chemical functionalisation methods and sensing applications of graphene. Building from a general overview of graphene chemistry and characterisation techniques, applicable to several areas of graphene R&D, the webinar will then focus on the development of graphene sensors and in particular biosensors. Following a brief review of different sensing techniques, including optical, various electrochemical, and FET based devices, the webinar will focus on electrochemical and CHEMFET biosensors. The suitability of different types of graphene for sensing applications will be discussed.
  • Silver nanoparticles have extraordinary properties at the nanoscale, which are enabling a wave of innovative commercial products. Many of these new applications are in the field of bionanotechnology where the strong interaction between silver nanoparticles and specific wavelengths of light is utilized for applications such as sensing, imaging and therapeutics. This webinar will discuss the fundamentals of silver nanoparticle physics, the effect of the nanoparticle’s surface on the stability, dissolution, and transport of the nanoparticles in biological systems, and will describe both current and future biotechnology applications of silver nanoparticles.
  • This workshop will introduce Corning® HepatoCells for ADME/Tox study. Derived from primary human hepatocytes, Corning HepatoCells are a renewable hepatocyte-like cell line and retain most of the physiological properties of their parental hepatocytes, such as mature hepatocyte-like morphology and induction response to prototypical inducers of CYP3A4, 1A2, and 2B6 similar to primary human hepatocytes. An overview of the characterization of Corning HepatoCells for ADME/Tox studies will be presented, along with using the model system for prediction of clinical CYP induction. The attendees will gain an understanding of the capability of Corning Hepatocyte-cells for drug ADME/Tox study.
  • Hygienic design, regulations & compliances are increasing dramatically in the Food & Beverage market. Consequently, the questions raised are: how can you ensure food safety? How does Hygienic Design support the cleanability & Total Cost of Ownership of your plant? And with a practical example: What does a perfect flowmeter for liquids look like?

    As well as speakers from Bürkert, this webinar features presentations from Hein Timmerman of Diversey-Sealed Air & Patrick Wouters of Cargill. Both are members of the European Hygienic Engineering & Design Group, EHEDG.

    Patrick will discuss Cargill’s overall goal to provide high quality, safe food, every time, everywhere; to this end, hygienic design is an important pre-requisite. This accounts for the choice of flow meters. Although hygienic design is a critical element, it is more important to have a correct measurement of the flow. This control point is of utmost importance, to ensure that specified functionality is achieved & food safety & product quality is ensured.

    Hein will discuss Sealed Air’s Value Added Services on cleaning applications & cleaning validations, which includes remote monitoring tools & software platforms to support their end customers’ requirements for food safety & Total Cost of Ownership.

    Bürkert’s John van Loon will discuss their new technology, FLOWave. This answers the hygiene issues other systems could face, by employing surface acoustic waves in a stainless steel tube. As such FLOWave allows a flow measurement of liquids without any parts within the tube. Current methods in industrial flow measurement are mainly based on moving parts like paddle wheels or rigid fixtures such as a bluff body in the measurement tube. These flow metering systems have their specific weaknesses, limiting their range of applications. The measuring task must be fulfilled, reliably, throughout the entire life cycle of the device. Also, the daily operative handling effort should remain within reasonable limits.
  • Wiley is pleased to present an AGU Author Webinar.

    If you’re looking to publish with the American Geophysical Union, this webinar will help you on your way. Over the course of 60 minutes, AGU editorial experts will cover:
    •The benefits of publishing with the AGU
    •A roadmap to successful AGU journal submission
    •Navigating the AGU peer review process
    •AGU’s guide to publication ethics
    •Plus your chance to ask questions

    Register today to hear from:
    Mary-Elena Carr, Editor, Global Biogeochemical Cycles
    Brooks Hanson, Director of Publications, American Geophysical Union
    Robert Pincus, Editor in Chief, Journal of Advances in Modeling Earth Systems
    Alan Robock, Editor, Reviews of Geophysics
  • Hear perspectives and insights from industry thought leaders regarding:
    - Hype vs. reality in real world applications of ‘big data’ systems in healthcare delivery?
    - Why now?
    - Through case studies some examples of plausible expectations for the scale and timeframe of ROI.
    - What changes in operations , infrastructure, and protocol is required to ensure maximum value of invested technologies?
  • Peter will share experiences and observations how the scientific high-tech community, can benefit from adopting paperless processes in the laboratory. Is it because paper doesn’t require any significant investment budget, or is it the low barrier to access, since paper even works without power or the need to have access to an information infrastructure, or is it just simply that the “what’s in it for me” question hasn’t been answered satisfactorily for the scientists?
    Cross-functional collaboration between research, development, quality assurance and manufacturing is all about optimising and integrating multi-discipline distributed processes from start-to- finish. A paperless electronic record keeping system will add significant value to support these goals. LIMS, SDMS, LES and ELN products all reduce variability, transcription errors. Do we believe that traditional paper based systems could ever support these complex processes?
  • An expert panel will provide perspectives on:
    - Why all information matters.
    - Adoption strategies for success & missteps to avoid in adoption.
    - Hidden links that can be drawn between seemingly disparate data sources to generate impactful insights for your organization.
    - Moving beyond just ordering drugs on the EMR, what impact have solutions had on quality, access, and cost.
    - Innovating to zero, use cases of systems to mitigate errors in care provision, wasteful spend, and administrative inefficiency.
    - Enabling new care services (precision medicine, population health, care virtualization)
  • Because of worldwide demographic changes a dramatic increase of the geriatric population is expected in the next decades. While pediatric drug delivery principles are becoming integrated into the development of new medicines, drug developers are less prepared to appropriately address the specific needs of this booming patient population. This webinar tries to give an overview about the possible drug delivery strategies addressing old age dependent differences. There will be specifically focused on how patient convenience and compliance can be improved, how disease specific drug delivery strategies can help geriatric patients, and how learnings from pediatric drug development can be used as a platform towards geriatric drug delivery.
  • Technology innovators will provide concepts and best practice considerations for integration. Hear their perspectives on:

    - Identifying ideal solution partners based on needs and use cases specific to your organization.
    - Building an information architecture framework, capable of evolving with your needs.
    - Cost of ownership considerations.
    - Decision Support Resources (real time, long term)
  • During the past decade, continuous processing has steadily gained traction within pharmaceutical industry. The smaller footprint, the reduction or minimization of technology transfer and overall flexibility of these systems generate the economic drivers for change. The advancement of technology, such as integration of process equipment and process analytical technology (PAT) enables concentrated process understanding and effective process control for these systems. There are an increasing number of joint efforts from industries, academia and regulatory agencies in this area. Continuous manufacturing implementations for commercial products are beginning to emerge as companies begin to turned this vision into reality.
    Among all the process analyzers, NIR is still one of the most widely used platform PAT tools in continuous processes. Some critical aspects should be considered for NIR (or other common PAT tools) implementation in continuous processes.
  • Monoclonal antibodies (mAbs) represent a big portion of therapeutic proteins. Mass spectrometry (MS) coupled with modern separation technologies has become an essential tool in characterization of mAbs within the Quality by Design (QbD) paradigm during development. In this article, we use case studies to discuss the application of MS analysis in clone selection, optimization of fermentation conditions, development of purification and formulation. Specifically, simultaneously detect and monitor variants due to incomplete leader sequence processing, accurately determine afucosylation level of N-glycosylation, characterize host cell proteins (HCPs), identify degradation pathways and critical quality attributes (CQAs) will be discussed.